Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Indikationer for radioimmunterapi til patienter med non-Hodgkins lymfom

Research output: Contribution to journalJournal articleResearch

  1. Gennemgang af Early Warning Scores til forebyggelse af uventet kritisk sygdom og død

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Limited evidence for therapy with medical cannabis in patients with bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Heart failure often accompanies diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mediastinal cyste som årsag til dårlig trivsel hos en ti måneder gammel dreng

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Konfusion, bevidsthedstab og uspecifikke synsgener kan være symptomer på demens med Lewy Bodies.

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. 87-årig kvinde påkørt af flugtbilist og helbredt for højmalignt lymfom

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Posterior reversibel encefalopati efterbehandling af malignt lymfom

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Translated title of the contributionIndications for radioimmunotherapy for patients with non-Hodgkin's lymphoma
Radioimmunotherapy is a well-known treatment for non-Hodgkin's lymphoma. (90)yttrium (Y)-ibritumomab-tiuxetan consists of a radioisotope conjugated to a monoclonal anti-cluster of differentiation 20 antibody, which is targeted against B-lymphocytes. Initially the treatment indication was relapse of low-grade non-Hodgkin's lymphoma. However, (90)Y-ibritumomab-tiuxetan has later been used in clinical trials in the treatment of other types of non-Hodgkin's lymphoma and prior to stem cell transplantation. Based on the literature this systematic review aims to throw light on the future possibilities of radioimmunotherapy.
Original languageDanish
JournalUgeskrift for Laeger
Volume173
Issue number20
Pages (from-to)1417-21
Number of pages5
ISSN0041-5782
StatePublished - 2011

ID: 34579273